Anteris Technologies Global Corp当前公司基本面数据相对健康,增长潜力稳定。当前估值合理,在医疗设备与耗材行业排名96/208位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价16.50。中期看,股价处于上升通道。近一个月,市场表现很强,技术面评分较高,但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。
Anteris Technologies Global Corp评分
相关信息
行业排名
96 / 208
全市场排名
226 / 4582
所属行业
医疗设备与耗材
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
4
位分析师
买入
评级
16.500
目标均价
+245.91%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
Anteris Technologies Global Corp亮点
亮点风险
Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
公司代码AVR
公司Anteris Technologies Global Corp
CEOPaterson (Wayne G)
网址https://anteristech.com/
常见问题
Anteris Technologies Global Corp(AVR)的当前股价是多少?
Anteris Technologies Global Corp(AVR)的当前股价是 5.320。
Anteris Technologies Global Corp的股票代码是什么?
Anteris Technologies Global Corp的股票代码是AVR。
Anteris Technologies Global Corp股票的52周最高点是多少?
Anteris Technologies Global Corp股票的52周最高点是8.790。
Anteris Technologies Global Corp股票的52周最低点是多少?
Anteris Technologies Global Corp股票的52周最低点是2.340。
Anteris Technologies Global Corp的市值是多少?
Anteris Technologies Global Corp的市值是191.85M。
Anteris Technologies Global Corp的净利润是多少?
Anteris Technologies Global Corp的净利润为-76.29M。
现在Anteris Technologies Global Corp(AVR)的股票是买入、持有还是卖出?
根据分析师评级,Anteris Technologies Global Corp(AVR)的总体评级为买入,目标价格为16.500。
Anteris Technologies Global Corp(AVR)股票的每股收益(EPS TTM)是多少
Anteris Technologies Global Corp(AVR)股票的每股收益(EPS TTM)是-2.341。